Literature DB >> 20170372

HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Nicole A Doria-Rose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20170372      PMCID： PMC2832095          DOI： 10.1086/651143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  36 in total

Review 1.  Clinical trials of HIV vaccines.

Authors:  Barney S Graham
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

2.  Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.

Authors:  E Beirnaert; P Nyambi; B Willems; L Heyndrickx; R Colebunders; W Janssens; G van der Groen
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

3.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Authors:  Zelda Euler; Marit J van Gils; Evelien M Bunnik; Pham Phung; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

4.  Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection.

Authors:  Jacob T Minang; Matthew T Trivett; Diane L Bolton; Charles M Trubey; Jacob D Estes; Yuan Li; Jeremy Smedley; Rhonda Pung; Margherita Rosati; Rashmi Jalah; George N Pavlakis; Barbara K Felber; Michael Piatak; Mario Roederer; Jeffrey D Lifson; David E Ott; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

5.  Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Marcus G Daniels; Sijy O'Dell; Martha Nason; Alan Lapedes; Tanmoy Bhattacharya; Stephen A Migueles; Richard T Wyatt; Bette T Korber; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

6.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

7.  Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Authors:  Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

9.  Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Authors:  Elin S Gray; Natasha Taylor; Diane Wycuff; Penny L Moore; Georgia D Tomaras; Constantinos Kurt Wibmer; Adrian Puren; Allan DeCamp; Peter B Gilbert; Blake Wood; David C Montefiori; James M Binley; George M Shaw; Barton F Haynes; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Authors:  Ann J Hessell; Pascal Poignard; Meredith Hunter; Lars Hangartner; David M Tehrani; Wim K Bleeker; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440
View more
  7 in total

Review 1.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

Review 2.  An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2014-11-18       Impact factor: 7.561

3.  Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.

Authors:  Georgina Bowyer; Tommy Rampling; Jonathan Powlson; Richard Morter; Daniel Wright; Adrian V S Hill; Katie J Ewer
Journal:  Vaccines (Basel)       Date:  2018-07-31

Review 4.  The Antibodiome-Mapping the Humoral Immune Response to HIV.

Authors:  Audrey L Butler; Stephanie Fischinger; Galit Alter
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

5.  Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children.

Authors:  Julia Roider; J Zachary Porterfield; Paul Ogongo; Maximilian Muenchhoff; Emily Adland; Andreas Groll; Lynn Morris; Penny L Moore; Thumbi Ndung'u; Henrik Kløverpris; Philip J R Goulder; Alasdair Leslie
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 6.  SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.

Authors:  Ralf Duerr; Keaton M Crosse; Ana M Valero-Jimenez; Meike Dittmann
Journal:  Microorganisms       Date:  2021-06-27

7.  High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults.

Authors:  Julia Roider; Takashi Maehara; Abigail Ngoepe; Duran Ramsuran; Maximilian Muenchhoff; Emily Adland; Toby Aicher; Samuel W Kazer; Pieter Jooste; Farina Karim; Warren Kuhn; Alex K Shalek; Thumbi Ndung'u; Lynn Morris; Penny L Moore; Shiv Pillai; Henrik Kløverpris; Philip Goulder; Alasdair Leslie
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.